Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731

Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing

Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447

Apolipoprotein E: Structure-Function Relationships

Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830

The Pathogenesis of Senile Plaques

DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493

Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474

Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

Triguero, D., Buciak, J. L., & Pardridge, W. M. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04886.x · Cited by 454

Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid

Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385

The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders

Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280

Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development

Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965

The role of apolipoprotein E in Alzheimer's disease

Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426

Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier

Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413

Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury

Shlosberg, D., Benifla, M., Kaufer, D., & Friedman, A. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.74 · Cited by 897

Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease

Bell, R. D., & Zloković, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 883

apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain

Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771

Therapeutics of Alzheimer's disease: Past, present and future

Anand, R., Gill, K. D., & Mahdi, A. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 765

Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System

Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670

Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease

Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

Deane, R., Bell, R. D., Sagare, A. P., & Zloković, B. V. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 559

Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus

Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524

Cerebral Amyloid Angiopathy: A Systematic Review

Biffi, A., & Greenberg, S. M. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.1.1 · Cited by 459

RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid β-Peptide Clearance Through Transport Across the Blood–Brain Barrier

Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392

Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor

Davis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373

Oxidative Stress Increases Blood–Brain Barrier Permeability and Induces Alterations in Occludin during Hypoxia–Reoxygenation

Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334

Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies

Révész, T., Holton, J. L., Lashley, T., Plant, G. T., Frangione, B., Rostagno, A. A., & Ghiso, J. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0501-8 · Cited by 300

Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes

Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., Painter, M. M., Sullivan, P. M., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.003 · Cited by 289

Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain

Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261

The blood–brain barrier in neurodegenerative disease: a rhetorical perspective

Carvey, P. M., Hendey, B., & Monahan, A. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06319.x · Cited by 260

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242

Apolipoprotein E: Diversity of Cellular Origins, Structural and Biophysical Properties, and Effects in Alzheimer's Disease

Huang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242

IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

Deane, R., Sagare, A. P., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zloković, B. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 238

Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease

Martins, I. J., Berger, T. R., Sharman, M. J., Verdile, G., Fuller, S. J., & Martins, R. N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06408.x · Cited by 237

Development of the choroid plexus

Dzięgielewska, K. M., Ek, C. J., Habgood, M. D., & Saunders, N. R. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010101)52:1 · Cited by 245

Neurotherapeutic applications of nanoparticles in Alzheimer’s disease

Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219

APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis

Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212

Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1

Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205

Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging

Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191

Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives

Cheng, Y., Tian, D., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 197

Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier

Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

Deane, R., Sagare, A. P., & Zloković, B. V. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705487 · Cited by 188

High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease

Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 183

The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease

Raha, A. A., Vaishnav, R., Friedland, R. P., Bomford, A. B., & Raha‐Chowdhury, R. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-55 · Cited by 183

Interaction between blood-brain barrier and glymphatic system in solute clearance

Verheggen, I. C. M., van Boxtel, M. P. J., Verhey, F. R. J., Jansen, J. F. A., & Backes, W. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.028 · Cited by 171

The role of apolipoprotein E in Alzheimer’s disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models

Horsburgh, K. J., McCarron, M. O., White, F., & Nicoll, J. A. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00097-x · Cited by 169

Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease

Bergamaschini, L., Rossi, E., Storini, C., Pizzimenti, S., Distaso, M., Perego, C., De Luigi, A., Vergani, C., & Grazia De Simoni, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0550-04.2004 · Cited by 146

Plasma levels of apolipoprotein Eand risk of dementia in the general population

Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156

Exercise, cognition and Alzheimer's disease: More is not necessarily better

Eggermont, L. H. P., Swaab, D. F., Luiten, P. G. M., & Scherder, E. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.10.004 · Cited by 156

The Choroid Plexus Removes β-Amyloid from Brain Cerebrospinal Fluid

Crossgrove, J. S., Li, G. J., & Zheng, W. (2005) · Experimental Biology and Medicine · doi:10.1177/153537020523001011 · Cited by 149

ApoE3 Mediated Poly(butyl) Cyanoacrylate Nanoparticles Containing Curcumin: Study of Enhanced Activity of Curcumin against Beta Amyloid Induced Cytotoxicity Using In Vitro Cell Culture Model

Mulik, R. S., Mönkkönen, J., Juvonen, R. O., Mahadik, K. R., & Paradkar, A. R. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900306x · Cited by 150

Neurovascular Defects and Faulty Amyloid-β Vascular Clearance in Alzheimer's Disease

Sagare, A. P., Bell, R. D., & Zloković, B. V. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129037 · Cited by 152

Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities

Sagare, A. P., Deane, R., & Zloković, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 148

LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier

Pflanzner, T., Janko, M. C., André-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J. M., Kuhlmann, C. R. W., & Pietrzik, C. U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.025 · Cited by 141

Challenges associated with curcumin therapy in Alzheimer disease

Belkacemi, A., Doggui, S., Dao, L. H., & Ramassamy, C. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002055 · Cited by 131

Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review

Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125

Current therapeutic targets for the treatment of Alzheimer’s disease

Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123

Curcumin in Alzheimer’s disease: Can we think to new strategies and perspectives for this molecule?

Serafini, M. M., Catanzaro, M., Rosini, M., Racchi, M., & Lanni, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.004 · Cited by 119

Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease

Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V, Fallon, J., Kuo-Leblanc, V, Glass, D., Hulette, C., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00288-5 · Cited by 113

Precision pharmacology for Alzheimer’s disease

Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114

Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier

Ito, S., Ohtsuki, S., & Terasaki, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.07.006 · Cited by 99

Lipids and Cognition

Morley, J. E., & Banks, W. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091576 · Cited by 108

Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood

Monro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107

Apolipoprotein E and Alzheimer disease

Huang, Y. (2006) · Neurology · doi:10.1212/01.wnl.0000192102.41141.9e · Cited by 105

Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin‐bound and free iron into the rat brain

Deane, R., Zheng, W., & Zloković, B. V. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02221.x · Cited by 104

Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke

Zerche, M., Weißenborn, K., Ott, C., Dere, E., Asif, A. R., Worthmann, H., Hassouna, I. A., Rentzsch, K., Tryc, A. B., Dahm, L., et al. (2015) · Stroke · doi:10.1161/strokeaha.114.008323 · Cited by 90

Alzheimer’s disease and its treatment–yesterday, today, and tomorrow

Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99

CD45 Deficiency Drives Amyloid-β Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice

Zhu, Y., Hou, H., Rezai-Zadeh, K. P., Giunta, B. N., Ruscin, A., Gemma, C., Jin, J., Dragicevic, N., Bradshaw, P. C., Rasool, S., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3268-10.2011 · Cited by 90

Oligomerization and fibril assembly of the amyloid-β protein

Roher, A. E., Baudry, J. Y., Chaney, M. O., Kuo, Y., Stine, W. B., & Emmerling, M. R. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00030-2 · Cited by 89

Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort

Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86

Apolipoprotein E, Amyloid-β, and Blood-Brain Barrier Permeability in Alzheimer Disease

Donahue, J. E., & Johanson, C. E. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a0dc8 · Cited by 87

Receptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier

Poduslo, J. F., Curran, G. L., Sanyal, B., & Selkoe, D. J. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0238 · Cited by 83

Glycoprotein 330/Megalin (LRP-2) Has Low Prevalence as mRNA and Protein in Brain Microvessels and Choroid Plexus

Chun, J. T., Wang, L., Pasinetti, G. M., Finch, C. E., & Zlokovic, B. V. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7052 · Cited by 67

Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice

Liu, M., Kuhel, D. G., Shen, L., Hui, D. Y., & Woods, S. C. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00219.2012 · Cited by 82

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA)

Carare, R. O., Aldea, R., Agarwal, N., Bacskai, B. J., Bechman, I., Boche, D., Bu, G., Bulters, D. O., Alt, C., Counts, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12053 · Cited by 77

Endothelial Protein C Receptor-Assisted Transport of Activated Protein C across the Mouse Blood—Brain Barrier

Deane, R., LaRue, B., Sagare, A. P., Castellino, F., Zhong, Z., & Zloković, B. V. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.117 · Cited by 68

Elevated Aβ and Apolipoprotein E in AβPP Transgenic Mice and Its Relationship to Amyloid Accumulation in Alzheimer’s Disease

Kuo, Y., Crawford, F., MULLAN, M. J., Kokjohn, T. A., Emmerling, M. R., Weller, R. O., & Roher, A. E. (2000) · Molecular Medicine · doi:10.1007/bf03401785 · Cited by 68

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., & Melone, M. A. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111897 · Cited by 70

Hypertension and Cognitive Function

Obisesan, T. O. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.03.002 · Cited by 71

MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer’s disease

Ringland, C., Schweig, J. E., Eisenbaum, M., Paris, D., Ait‐Ghezala, G., MULLAN, M. J., Crawford, F., Abdullah, L. I., & Bachmeier, C. J. (2021) · BMC Neuroscience · doi:10.1186/s12868-021-00643-2 · Cited by 68

Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets

Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 63

Modulation of Amyloid-β1–40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier

Merino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63

Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease

Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.041 · Cited by 63

Amyloid and lipids in the pathology of Alzheimer disease

Roher, A. E., Kuo, Y., Kokjohn, K., Emmerling, M. R., & Gracon, S. I. (1999) · Amyloid · doi:10.3109/13506129909007315 · Cited by 63

Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease?

Mohajeri, M., Behnam, B., Barreto, G. E., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.023 · Cited by 61

In Vitro Evidence That β-Amyloid Peptide 1–40 Diffuses Across the Blood–Brain Barrier and Affects Its Permeability

Strazielle, N., Ghersi‐Egea, J., Ghiso, J. A., Dehouck, M., Frangione, B., Patlak, C. S., Fenstermacher, J. D., & Gorevic, P. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.29 · Cited by 60

Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels

Zhang, Y., & Lee, D. H. S. (2011) · The Neuroscientist · doi:10.1177/1073858410381532 · Cited by 61

Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer’s Disease and in Down Syndrome Dementia

Raha‐Chowdhury, R., Henderson, J. W., Raha, A. A., Vuono, R., Bickerton, A., Jones, E. A., Fincham, R., Allinson, K. S. J., Holland, A. J., & Zaman, S. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181179 · Cited by 57

Method for measurement of the blood–brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer’s Tg2576 mice

LaRue, B., Hogg, E., Sagare, A. P., Jovanovic, S. S., Maness, L. M., Maurer, C. R., Deane, R., & Zloković, B. V. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.04.026 · Cited by 59

Anti-Aβ-MAb and dually decorated nanoliposomes: Effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells

Markoutsa, E., Παπαδιά, Κ., Clemente, C., Flores, O., & Antimisiaris, S. G. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.006 · Cited by 56

Cerebral Amyloid Angiopathy, Subcortical White Matter Disease and Dementia: Literature Review and Study in OPTIMA

Esiri, M. M., Chance, S. A., Joachim, C. L., Warden, D. R., Smallwood, A., Sloan, C., Christie, S., Wilcock, G. K., & Smith, A. D. (2014) · Brain Pathology · doi:10.1111/bpa.12221 · Cited by 56

Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats

Iwata, A., Browne, K. D., Chen, X., Yuguchi, T., & Smith, D. H. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20607 · Cited by 53

Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity

Singh, A., Kumar, A., Verma, R. K., & Shukla, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.041 · Cited by 53

Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy

Tosi, G., Pederzoli, F., Belletti, D., Vandelli, M. A., Forni, F., Duskey, J. T., & Ruozi, B. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.001 · Cited by 53

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy

Camacho, J., Moliné, T., Bonaterra‐Pastra, A., y Cajal, S. R., Martínez-Sáez, E. A., & Hernández‐Guillamón, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00187 · Cited by 52

Apolipoprotein E in Cerebrospinal Fluid: Relation to Phenotype and Plasma Apolipoprotein E Concentrations

Yamauchi, K., Tozuka, M., Nakabayashi, T., Sugano, M., Hidaka, H., Kondo, Y., & Katsuyama, T. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.4.497 · Cited by 50

Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing

Bachmeier, C. J., Shackleton, B., Ojo, J. O., Paris, D., MULLAN, M. J., & Crawford, F. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8318-6 · Cited by 50

A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 53

Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models

Huang, Y. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390924 · Cited by 53

Alzheimer’s Disease and the Blood–Brain Barrier: Past, Present and Future

Bowman, G. L., & Quinn, J. F. (2008) · Aging Health · doi:10.2217/1745509x.4.1.47 · Cited by 43

In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein

McIntee, F. L., Giannoni, P., Blais, S. P., Sommer, G., Neubert, T. A., Rostagno, A. A., & Ghiso, J. A. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42

Constitutive overactivation of protein kinase C in guinea pig brain increases α‐secretory APP processing without decreasing β‐amyloid generation

Roßner, S., Beck, M., Stahl, T., Mendla, K. D., Schliebs, R., & Bigl, V. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00211.x · Cited by 41

Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer’s disease

Zhang, L., Postina, R., & Wang, Y. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0121-4 · Cited by 40

Recent Insights on Alzheimer’s Disease Originating from Yeast Models

Seynnaeve, D., Vecchio, M. D., Fruhmann, G., Verelst, J., Cools, M., Beckers, J., Mulvihill, D. P., Winderickx, J., & Franssens, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071947 · Cited by 39

Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties

Rempe, R. G., Cramer, S., Qiao, R., & Galla, H. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1819-7 · Cited by 38

APOE genetic associations with seizure development after severe traumatic brain injury

Miller, M. A., Conley, Y. P., Scanlon, J. M., Ren, D., Kamboh, M. I., Niyonkuru, C., & Wagner, A. K. (2010) · Brain Injury · doi:10.3109/02699052.2010.520299 · Cited by 37

Regulation of cholesterol efflux by amyloid β secretion

Umeda, T., Mori, H., Zheng, H., & Tomiyama, T. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22360 · Cited by 34

Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain

Fujita, S. C., Sakuta, K., Tsuchiya, R., & Hamanaka, H. (1999) · Neuroscience Research · doi:10.1016/s0168-0102(99)00075-9 · Cited by 32

Serum apolipoprotein E is associated with long-term risk of Alzheimer’s disease: The Rotterdam Study

Wolters, F. J., Koudstaal, P. J., Hofman, A., Duijn, C. M. V., & Ikram, M. A. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.018 · Cited by 31

Cerebrovascular transport of Alzheimer's amyloidβ and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier

Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 139

Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid β

Zloković, B. V., Martel, C. L., Mačkić, J. B., Matsubara, E., Wısnıewskı, T., McComb, J. G., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2825 · Cited by 133

A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 53

Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs

Martel, C. L., Mackic, J. B., McComb, J. G., Ghiso, J., & Zlokovic, B. V. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12462-9 · Cited by 69

Blood-Brain Barrier Transport of Circulating Alzheimer′s Amyloid β

Zlokovic, B. V., Ghiso, J., Mackic, J. B., Mccomb, J. G., Weiss, M. H., & Frangione, B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2582 · Cited by 150